LncGata6-controlled stemness in regeneration and cancer
Editorial

LncGata6-controlled stemness in regeneration and cancer

Youn-Sang Jung1#, Moon Jong Kim1#, Jae-Il Park1,2,3

1Department of Experimental Radiation Oncology, 2Program in Genetics and Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center and Health Science Center, Houston, TX, USA

#These authors contributed equally to this work.

Correspondence to: Jae-Il Park. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Email: jaeil@mdanderson.org; jaeil1020@gmail.com.

Provenance: This is an invited Editorial commissioned by Dr. Rongrong Gao, Section Editor (Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China).

Comment on: Zhu P, Wu J, Wang Y, et al. LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis. Nat Cell Biol 2018;20:1134-44.


Received: 01 January 2019; Accepted: 03 January 2019; Published: 15 January 2019.

doi: 10.21037/ncri.2019.01.02


Long-noncoding RNAs (lncRNAs) have been proposed as a critical regulator of various cellular processes including cell fate decision and cell proliferation (1,2). Mechanistically, lncRNAs control various gene expressions by recruiting the chromatin modifiers in cis and trans modes (1). Transcription of lncRNAs itself also can activate or suppress the neighboring gene expression by the transcriptional interference through regulatory sequences (1,3). lncRNAs are also involved in a wide range of protein and RNA regulatory functions, such as scaffoldings of proteins and RNAs, protein and RNA decoys, and functional micro-peptides production (1). Aberrant regulation of lncRNA-mediated cellular processes is implicated in human disease including cancer (4,5). The recent technologic advance including the single-cell RNA sequencing (scRNA-seq), and gene editing, genetically engineered mouse (GEM) models has made it feasible to elucidate the various roles of lncRNAs in the normal tissue physiology and the pathologic conditions including tumorigenesis and metastasis (2,6).

Intestinal stem cells (ISCs) have been considerably studied among tissue stem cells, mainly due to constitutive replenishment of intestinal epithelium (3 to 4 days) and availability of various GEM models visualizing the ISCs and progenitor cells (7). The intestinal crypts include two different types of ISCs: the highly proliferative crypt bottom columnar (CBC) ISCs (marked by Lgr5, Ascl2, or Olfm4) and the relatively quiescent ISCs (qISCs) (labeled with Bmi1 or Tert). CBC ISCs constitutively divide into the progenitor cells for intestinal homeostasis (8) whereas qISCs become mitotic for intestinal regeneration upon injury (9,10). Additionally, cell plasticity takes place for interconversion between CBC ISCs and qISCs. For example, Lgr5+ ISCs are generated from Bmi1 and Tert+ ISCs during radiation-induced intestinal regeneration (9,10). Wnt/β-catenin signaling is activated in the intestinal crypts by Wnt agonists secreted from the mesenchymal cells and the Paneth cells (11,12). Such endogenous Wnt/β-catenin signaling activity is required for the constitutive division of CBC ISCs and the terminal differentiation into the Paneth cells (11,13). Upon radiation injury, Wnt2b is upregulated and hyperactivates Wnt/β-catenin signaling in Tert+ ISCs, which leads to the quiescence exit of Tert+ ISCs for intestinal regeneration (10). In addition to developmental signaling, WINTRLiNC1, a neighboring cis-LncRNA of ASCL2 upregulates ASCL2, a regulator of ISCs, in colorectal cancer (CRC) cells (14), implying the potential involvement of lncRNAs in intestinal homeostasis and regeneration.

With an extensive collection of experiments, Zhu et al. recently identified LncGata6 as a regulator of stemness in ISCs and CRC (15) (Figure 1). Using the Lgr5 reporter knock-in mouse, and organoid system, they found that LncGata6 expression is specifically enriched in the Lgr5+ ISCs and required for ISC-derived organoid growth. Similarly, genetic ablation of LncGata6 impairs both intestinal homeostasis and regeneration in GEM models. Mechanistically, LncGata6 recruits the NURF (nucleosome remodeling factor) complex to the promoter of Ets homologous factor (EHF) and transactivates EHF expression. EHF was shown to enhance the expression of Lgr4/5 receptors, which subsequently hyperactivates Wnt/β-catenin signaling. Based on these results, the authors proposed that the specific expression of LncGata6 is indispensable for Wnt/β-catenin signaling activation for intestinal homeostasis as well as regeneration.

Figure 1 Schematic illustration of LncGata6-controlled intestinal regeneration and cancer. LncGata6 binds to BPTF, a component of the NURF complex, for chromatin remodeling. The PHD finger of BPTF recognizes the methylated histone H3. The bromodomain serves as a histone acetylated lysine recognition domain. SNF2L and RCAP46/48, subunits of the NURF complex, then induce the chromatin remodeling for EHF transactivation, which leads to activation of Wnt/β-catenin signaling. LncGata6 is enriched in the intestinal stem cells and activates Wnt/β-catenin signaling for intestinal homeostasis and regeneration. However, aberrant upregulation of LncGata6 hyperactivates Wnt/β-catenin signaling via EHF, resulting in intestinal tumorigenesis. NURF, nucleosome remodeling factor; EHF, Ets homologous factor; PHD, plant homeodomain.

Intriguingly, this study demonstrated that lncRNA is physically and functionally associated with the epigenetic modality in modulating tissue stem cells. Epigenetic regulation including histone modification and chromatin remodeling plays vital roles in controlling the stemness maintenance and differentiation in human and mouse embryonic stem cells (16). In hepatocellular carcinoma, LncTCF7 promotes the self-renewal of cancer stem cells (CSCs) by activating Wnt/β-catenin signaling via recruiting the SWI/SNF (switch/sucrose non-fermenting) histone modifier to TCF7 promoter (17), which is functionally similar to the action of LncGata6 in transactivating EHF in Lgr5+ ISCs. Due to lncRNAs’ versatile mode of gene regulation and their implication in the epigenetic modification, it is highly plausible that LncGata6-mediated recruitment of the NURF complex to the target promoters might transactivate other vital genes in addition to EHF. Thus, it is necessary to unveil the genome-wide impacts of LncGata6 on the NURF-associated epigenetic gene regulation. Moreover, authors showed that EHF mediates LncGata6-activated Wnt/β-catenin signaling. Intriguingly, LncGata6 also regulates the expression of ISCs-associated transcriptional factors including Myb, Fosb, and Sox9. Thus, it remains possible that LncGata6-controlled ISCs might also be due to the systemic changes in the transcriptional landscape rather than EHF upregulation per se, which should be addressed in future studies.

Abnormal expression of lncRNA is associated with cancer (4). In CRC, lncRNA contributes to therapeutic resistance and malignancy (5). Zhu et al. revealed that LncGata6 is implicated in the development of CRC. The authors found that LncGata6 is highly expressed in CRC patients. Moreover, the loss of LncGata6 inhibits CRC development in the ApcMIN CRC GEM model and patient-derived xenograft (PDX). These results suggest that LncGata6 also functions as a positive regulator of Wnt/β-catenin signaling in CRC. Similar to the mechanism of LncGata6-activated Wnt signaling in the ISCs, LncGata6 hyperactivates Wnt/β-catenin signaling through the NURF complex in CRC. The NURF complex is implicated in the intestinal tumorigenesis via SMARCA1 (18). The NURF complex is composed of bromodomain PHD finger transcription factor (BPTF), SNF2L, ATPase subunit, and pRBAP46/48 (19). Zhu et al. showed that LncGata6 binds to BPTF of the NURF complex and transactivates EHF. EHF is highly expressed in human cancers including CRC, lung cancer, and liver cancer (20). However, how EHF is upregulated in cancer was unknown. Thus, LncGata6-mediated transcriptional activation of EHF might explain the upregulation of EHF in human cancer in general. BPTF induces the epithelial-mesenchymal transition (EMT) (21) and enhances the transcription activity of MYC in CRC (22). Given that the NURF complex upregulates Wnt/β-catenin signaling (23), it is likely that LncGata6 might also contribute to EMT and MYC-activated transcriptional network via the NURF complex. Future studies may address how LncGata6 contributes to CRC metastasis.

Genetic or epigenetic hyperactivation of Wnt/β-catenin signaling directly initiates intestinal tumorigenesis. More than 75% of CRC patients exhibit aberrant activation of Wnt/β-catenin signaling, which is mainly due to the genetic mutations in the Wnt signaling core components including CTNNB1/β-catenin and β-catenin destruction components [adenomatous polyposis coli (APC) and AXIN] (24). To the present, various attempts have been made to manipulate Wnt/β-catenin for CRC treatment. The authors’ discovery proposed targeting of LncGata6 as a new method for inhibiting Wnt/β-catenin signaling and suppressing intestinal tumorigenesis. Indeed, Zhu et al. showed that the blockade of LncGata6 increases the survival rate of the ApcMIN mice with reduced tumor development. Intriguingly, LncGata6 inhibition also suppressed the intestinal tumorigenesis in AOM (azoxymethane)/DSS (dextran sulfate sodium)-treated mice, an inflammation-associated CRC model (25). These results bring speculation that LncGata6 may also contribute to inflammatory CRC, somewhat independently of Wnt/β-catenin signaling.

Given the crucial roles of LncGata6 in intestinal homeostasis and regeneration, a pre-clinical test should carefully examine the side effects and consider the specific and efficient delivery methods of LncGata6 targeting reagents to CRC. Despite the co-expression of LncGata6 with Lgr5, defining CSCs by LncGata6 expression may require additional evidence. Furthermore, it is unknown how LncGata6 is upregulated in CRC. Nonetheless, considering the impacts of CSCs on therapeutic resistance and metastasis, a study of LncGata6 in CRC therapeutic resistance and metastasis might be interesting. Additionally, expression of LncGata6 and EHF might serve as biomarkers for CRC patients for treatment with LncGata6 molecular targeting. Together, Zhu et al. unveiled how lncRNA governs cell stemness in both physiologic and pathologic conditions and further proposed molecular targeting of lncRNA as a viable option for CRC treatment.


Acknowledgements

Funding: This work was supported by the Cancer Prevention Research Institute of Texas (RP140563 to JI Park), the National Institutes of Health (R01 CA193297-01 to JI Park), the Department of Defense Peer Reviewed Cancer Research Program (CA140572 to JI Park), a Duncan Family Institute for Cancer Prevention and Risk Assessment Grant (IRG-08-061-01 to JI Park), a Center for Stem Cell and Developmental Biology Transformative Grant (MD Anderson Cancer Center to JI Park), an Institutional Research Grant (MD Anderson Cancer Center to JI Park), and a Uterine SPORE Career Enhancement Program (MD Anderson to JI Park).


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Flynn RA, Chang HY. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell 2014;14:752-61. [Crossref] [PubMed]
  2. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 2018;19:143-57. [Crossref] [PubMed]
  3. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013;152:1298-307. [Crossref] [PubMed]
  4. Schmitt AM, Chang HY. Long Noncoding RNAs in Cancer Pathways. Cancer Cell 2016;29:452-63. [Crossref] [PubMed]
  5. Huarte M. The emerging role of lncRNAs in cancer. Nat Med 2015;21:1253-61. [Crossref] [PubMed]
  6. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012;9:703-19. [Crossref] [PubMed]
  7. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat Rev Mol Cell Biol 2014;15:19-33. [Crossref] [PubMed]
  8. Snippert HJ, van der Flier LG, Sato T, et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 2010;143:134-44. [Crossref] [PubMed]
  9. Yan KS, Chia LA, Li X, et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci U S A 2012;109:466-71. [Crossref] [PubMed]
  10. Suh HN, Kim MJ, Jung YS, et al. Quiescence Exit of Tert(+) Stem Cells by Wnt/beta-Catenin Is Indispensable for Intestinal Regeneration. Cell Rep 2017;21:2571-84. [Crossref] [PubMed]
  11. Farin HF, Van Es JH, Clevers H. Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells. Gastroenterology 2012;143:1518-29.e7. [Crossref] [PubMed]
  12. Kim KA, Kakitani M, Zhao J, et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 2005;309:1256-9. [Crossref] [PubMed]
  13. Pinto D, Gregorieff A, Begthel H, et al. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev 2003;17:1709-13. [Crossref] [PubMed]
  14. Giakountis A, Moulos P, Zarkou V, et al. A Positive Regulatory Loop between a Wnt-Regulated Non-coding RNA and ASCL2 Controls Intestinal Stem Cell Fate. Cell Rep 2016;15:2588-96. [Crossref] [PubMed]
  15. Zhu P, Wu J, Wang Y, et al. LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis. Nat Cell Biol 2018;20:1134-44. [Crossref] [PubMed]
  16. Young RA. Control of the embryonic stem cell state. Cell 2011;144:940-54. [Crossref] [PubMed]
  17. Wang Y, He L, Du Y, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 2015;16:413-25. [Crossref] [PubMed]
  18. Liu T, Han Z, Li H, et al. LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3. Mol Cancer 2018;17:118. [Crossref] [PubMed]
  19. Landry JW, Banerjee S, Taylor B, et al. Chromatin remodeling complex NURF regulates thymocyte maturation. Genes Dev 2011;25:275-86. [Crossref] [PubMed]
  20. Jedlicka P, Gutierrez-Hartmann A. Ets transcription factors in intestinal morphogenesis, homeostasis and disease. Histol Histopathol 2008;23:1417-24. [PubMed]
  21. Xiao S, Liu L, Lu X, et al. The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin. J Cancer Res Clin Oncol 2015;141:1465-74. [Crossref] [PubMed]
  22. Richart L, Carrillo-de Santa Pau E, Rio-Machin A, et al. BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. Nat Commun 2016;7:10153. [Crossref] [PubMed]
  23. Song H, Spichiger-Haeusermann C, Basler K. The ISWI-containing NURF complex regulates the output of the canonical Wingless pathway. EMBO Rep 2009;10:1140-6. [Crossref] [PubMed]
  24. Nusse R, Clevers H. Wnt/beta-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell 2017;169:985-99. [Crossref] [PubMed]
  25. Tanaka T. Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. Int J Inflam 2012;2012:658786. [Crossref] [PubMed]
doi: 10.21037/ncri.2019.01.02
Cite this article as: Jung YS, Kim MJ, Park JI. LncGata6-controlled stemness in regeneration and cancer. Non-coding RNA Investig 2019;3:4.